Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy

• Type: Article in International Scientific Journal
• Date: 2019

Authors

Martins, C (Author) Other; Araujo, F (Author) Other; Gomes, MJ (Author) Other; Fernandes, C (Author) Other; Nunes, R (Author) Other; Li, W (Author) Other; Santos, HA (Author) Other; Fernanda Borges (Author) FCUP; Sarmento, B (Author) Other

Journal

Title: European Journal of Pharmaceutics and Biopharmaceutics

Vol. 138

Pages: 111-124

ISSN: 0939-6411

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 50 Citations

Scopus - 61 Citations

Other information

Authenticus ID: P-00Q-KSR

DOI: 10.1016/j.ejpb.2018.01.014

Abstract (EN): The human immunodeficiency virus (HIV) uses the brain as reservoir, which turns it as a promising target to fight this pathology. Nanoparticles (NPs) of poly(lactic-co-glycolic) acid (PLGA) are potential carriers of anti-HIV drugs to the brain, since most of these antiretrovirals, as efavirenz (EFV), cannot surpass the blood-brain barrier (BBB). Forasmuch as the conventional production methods lack precise control over the final properties of particles, microfluidics emerged as a prospective alternative. This study aimed at developing EFV-loaded PLGA NPs through a conventional and microfluidic method, targeted to the BBB, in order to treat HIV neuropathology. Compared to the conventional method, NPs produced through microfluidics presented reduced size (73 nm versus 133 nm), comparable polydispersity (around 0.090), less negative zeta-potential (-14.1 mV versus -28.0 mV), higher EFV association efficiency (80.7% versus 32.7%) and higher drug loading (10.8% versus 3.2%). The microfluidics-produced NPs also demonstrated a sustained in vitro EFV release (50% released within the first 24 h). NPs functionalization with a transferrin receptor-binding peptide, envisaging BBB targeting, proved to be effective concerning nuclear magnetic resonance analysis (delta = -0.008 ppm; delta = -0.017 ppm). NPs demonstrated to be safe to BBB endothelial and neuron cells (metabolic activity above 70%), as well as non hemolytic (1-2% of hemolysis, no morphological alterations on erythrocytes). Finally, functionalized nanosystems were able to interact more efficiently with BBB cells, and permeability of EFV associated with NPs through a BBB in vitro model was around 1.3-fold higher than the free drug.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14